In a leaked ab­stract, J&J's cell ther­a­py ap­pears to have dra­mat­ic ben­e­fits for mul­ti­ple myelo­ma pa­tients

Pa­tients tak­ing Leg­end Biotech and John­son & John­son’s can­cer cell ther­a­py Carvyk­ti had a 74% re­duc­tion in the risk of mul­ti­ple myelo­ma pro­gres­sion or death, ac­cord­ing to a leaked ab­stract from an up­com­ing med­ical meet­ing.

The da­ta, which emerged Tues­day night and have since been tak­en down, could put Carvyk­ti ahead of com­peti­tor Abec­ma, a CAR-T de­vel­oped by Bris­tol My­ers Squibb and 2sev­en­ty bio, in ear­li­er lines of treat­ment if and when it’s ap­proved for those in­di­ca­tions. The study’s re­sults sur­prised an­a­lysts, with a Cowen an­a­lyst de­scrib­ing it as “game-chang­ing ef­fi­ca­cy,” and sent Leg­end’s shares $LEGN 14% high­er af­ter Wednes­day’s open­ing bell.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER